Previously, it was found that the MIP-1b was inversely associated with COVID-19, indicating a protective role of MIP-1b in COVID-19 vulnerability and hospitalization [24], whereas MDC concentrations were decreased in mild to severe/critical patients, and the lowest levels of MDC were detected during the late phases of disease in severe/critical patients [25]. This evidence concerns the gene CCL4 and COVID-19.